These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Zoledronic acid and osteonecrosis of the jaw: incidence varies with use. Wynn RL Gen Dent; 2011; 59(5):330-2. PubMed ID: 22313815 [No Abstract] [Full Text] [Related]
8. Tonic-clonic seizure as the presentation symptom of severe hypocalcemia secondary to zoledronic acid administration. Navarro M; López R; Alaña M; Ocaña A; Leno R; Sánchez F; Fonseca E; Cruz JJ J Palliat Med; 2007 Dec; 10(6):1226-7. PubMed ID: 18095793 [No Abstract] [Full Text] [Related]
9. Short-term safety assessment in the use of intravenous zoledronic acid in children. Högler W; Yap F; Little D; Ambler G; McQuade M; Cowell CT J Pediatr; 2004 Nov; 145(5):701-4. PubMed ID: 15520785 [TBL] [Abstract][Full Text] [Related]
10. "Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe. Lugassy G Oncologist; 2005 May; 10(5):309-10; author reply 311-2. PubMed ID: 15851782 [No Abstract] [Full Text] [Related]
11. Re: Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. Diel IJ; Bergner R Oncologist; 2005 Jan; 10(1):82-3; author reply 84-7. PubMed ID: 15632256 [No Abstract] [Full Text] [Related]
12. Annual zoledronic acid for osteoporosis. BMJ Group Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701 [TBL] [Abstract][Full Text] [Related]
13. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Anastasilakis AD; Polyzos SA; Makras P; Sakellariou GT; Bisbinas I; Gkiomisi A; Delaroudis S; Gerou S; Ballaouri I; Oikonomou D; Papapoulos SE Bone; 2012 May; 50(5):1130-4. PubMed ID: 22366634 [TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis. Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098 [TBL] [Abstract][Full Text] [Related]
15. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. Dicuonzo G; Vincenzi B; Santini D; Avvisati G; Rocci L; Battistoni F; Gavasci M; Borzomati D; Coppola R; Tonini G J Interferon Cytokine Res; 2003 Nov; 23(11):649-54. PubMed ID: 14651779 [TBL] [Abstract][Full Text] [Related]
16. The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass. Anastasilakis AD; Polyzos SA; Delaroudis S; Bisbinas I; Sakellariou GT; Gkiomisi A; Papadopoulou E; Gerou S; Makras P Clin Endocrinol (Oxf); 2012 Dec; 77(6):816-22. PubMed ID: 22676573 [TBL] [Abstract][Full Text] [Related]
18. Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases. Joensuu TK Urol Int; 2008; 80(4):448-50. PubMed ID: 18587260 [TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721 [TBL] [Abstract][Full Text] [Related]
20. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]